Collection medium for whole blood
US4782026A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 25, 1985 |
| Grant date | Nov 1, 1988 |
| Priority date | — |
| Expiry date | Feb 25, 2005 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/108331
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An inhibitor of Platelet Factor 3 activity is included in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Factor 3 activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.